8 results
The objective of this investigation is to describe visual outcomes and assess the safety at 12 months (330 - 420 days) post bilateral implantation of the AcrySof® IQ PanOptix* Presbyopia correcting IOL Model TFNT00.
Primary Objective:To demonstrate noninferiority of ACRYSOF IQ PanOptix presbyopia-correcting IOL Model TFNT00 to the AT LISA tri IOL Model 839MP in mean photopic binocular uncorrected intermediate (60 cm) visual acuity at Visit 4A.Secondary…
The primary statistical objective of this study is to describe mean differences in corneal staining (type and area), for OPTI-FREE EverMoist Multi-Purpose Disinfecting Solution compared to baseline.
The purpose of this pilot study is to compare the perception of straylight in patients with CE marked multifocal intraocular lenses, measured with 4 different straylight measuring devices..
The objective of this study is to prospectively evaluate postoperative visual outcomes in a series of patients bilaterally implanted with the FineVision Micro F IOL versus those bilaterally implanted with the AcrySof® IQ ReSTOR® Aspheric +3 D…
The objective of this study is to prospectively evaluate postoperative visual outcome in a series of patients bilaterally implanted with the AcrySof® IQ ReSTOR® Aspheric +3 D multifocal IOL versus those bilaterally implanted with the LENTIS® Mplus…
Primary Objective:The primary objective of this study is to demonstrate the long-term (3 years) favorable visual acuity and adverse event outcomes for the Clareon IOL compared to historical SPE rates as reported in EN ISO 11979-7:2014.Secondary…
The purpose of this study is to evaluate the efficacy and safety of brolucizumab used in a Treat- to-Control (TtC) regimen with maximum treatment intervals up to 20 weeks for the treatment of patients with neovascular age-related macular…